In response to the growing AMR crisis, the UN Interagency Coordination Group on Antimicrobial Resistance (IACG) – which was created following the UN High-Level Meeting on AMR in 2016 – released its seminal report with recommendations on how to curb the spread of AMR.
Over the past few weeks since the World Health Assembly, we’ve seen quality integrated into seminal reports and WHO action plans on antimicrobial resistance (AMR), drug procurement and universal health coverage (UHC). We’re excited to see links made across these issues.
The goal of Universal health coverage (UHC) is to ensure that all people obtain the health services they need without suffering financial hardship when paying for them.
Medicines are a major driver of quality, safety, equity, and cost of care in low and middle-income country health systems.
Corruption in the health sector can hurt health outcomes. Improving good governance can in turn help prevent health-related corruption.
The prevalence of poor-quality antimicrobial medicines is widespread throughout Africa and Asia in lower income countries and lower middle-income countries.
Since our ancestors began trading several millennia ago, counterfeit and substandard medicines have been a recurring problem, with history punctuated by crises in the supply of anti-microbials, such as fake cinchona bark in the 1600s and fake quinine in the 1800s.
The selection and spread of antimalarial drug resistance pose enormous challenges to the health of people living in tropical countries.
Falciparum malaria kills, and it particularly kills the rural poor. Artemisinin derivatives, such as artesunate, are a vital component of Plasmodium falciparum malaria treatment and control in the face of globally increasing antimalarial drug resistance.